hydroxyurea has been researched along with Acute Liver Injury, Drug-Induced in 32 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children." | 9.12 | Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007) |
| "We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years." | 5.17 | Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. ( Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013) |
| "Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children." | 5.12 | Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007) |
| "A 62-year-old man with refractory leukemia transformed from myelodysplastic syndrome was placed on hydroxyurea (hydroxycarbamide) at a daily dose of 500 mg." | 4.90 | [Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test]. ( Karigane, D; Kikuchi, T; Koda, Y; Mori, T; Nakajima, H; Okamoto, S; Shimizu, T; Toyama, T, 2014) |
| "Hydroxyurea (HU) is a ribonucleotide reductase inhibitor used to treat myeloproliferative diseases including polycythemia vera (PV) and essential thrombocythemia (ET)." | 3.74 | Hydroxyurea induced acute elevations in liver function tests. ( Hallam, MJ; Kolesar, JM, 2008) |
| " Conversely, DO mice lacking adverse liver pathology following zileuton exposure experienced decreased hepatic concentrations of resistin and increased concentrations of insulin and leptin, providing potential clues into mechanisms of toxicity resistance." | 1.56 | Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice. ( Bell, N; Gatti, DM; Harrill, AH; James, LP; Larson, GJ; Lyn-Cook, LE; Mattes, WB; Mayeux, PR; You, D, 2020) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| " HSA irreversible alkylation represents a model for other proteins to be potentially toxic and thus may help explain zileuton hepatotoxicity." | 1.34 | Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ( Chordia, MD; Li, F; Macdonald, TL; Woodling, KA, 2007) |
| "Treatment with WEB 2086, alone or in combination with Zileuton, did not inhibit LPS-mediated hepatic neutrophil infiltration or liver injury, as assessed by histologic evaluation and increases in plasma alanine aminotransferase activity." | 1.30 | Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. ( Bailie, MB; Fink, GD; Pearson, JM; Roth, RA, 1997) |
| "Because of the frequent reports of hepatic toxicity associated with long-term administration of methotrexate, a rat model was developed utilizing daily methotrexate administration." | 1.26 | Choline antagonism of methotrexate liver toxicity in the rat. ( Freeman-Narrod, M, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (31.25) | 18.7374 |
| 1990's | 5 (15.63) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 11 (34.38) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| You, D | 1 |
| Lyn-Cook, LE | 1 |
| Gatti, DM | 1 |
| Bell, N | 1 |
| Mayeux, PR | 1 |
| James, LP | 1 |
| Mattes, WB | 1 |
| Larson, GJ | 1 |
| Harrill, AH | 1 |
| Zhang, L | 1 |
| Huang, Y | 1 |
| Yu, Z | 1 |
| Shao, M | 1 |
| Luo, Y | 1 |
| Zhu, Y | 1 |
| Vichinsky, E | 1 |
| Torres, M | 1 |
| Minniti, CP | 1 |
| Barrette, S | 1 |
| Habr, D | 1 |
| Zhang, Y | 1 |
| Files, B | 1 |
| Shimizu, T | 1 |
| Mori, T | 1 |
| Karigane, D | 1 |
| Kikuchi, T | 1 |
| Koda, Y | 1 |
| Toyama, T | 1 |
| Nakajima, H | 1 |
| Okamoto, S | 1 |
| Thol, F | 1 |
| Schlenk, RF | 1 |
| Yen, Y | 1 |
| Chow, W | 1 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Morgan, R | 1 |
| Raschko, J | 1 |
| Shibata, S | 1 |
| Somlo, G | 1 |
| Twardowski, P | 1 |
| Frankel, P | 1 |
| Longmate, J | 1 |
| Synold, T | 1 |
| Newman, EM | 1 |
| Lenz, HJ | 1 |
| Gandara, D | 1 |
| Doroshow, JH | 1 |
| Watkins, PB | 1 |
| Dube, LM | 1 |
| Walton-Bowen, K | 1 |
| Cameron, CM | 1 |
| Kasten, LE | 1 |
| Li, F | 1 |
| Chordia, MD | 1 |
| Woodling, KA | 1 |
| Macdonald, TL | 1 |
| Hallam, MJ | 1 |
| Kolesar, JM | 1 |
| Hollard, D | 1 |
| Sotto, JJ | 1 |
| Berthier, R | 1 |
| Leger, J | 1 |
| Michallet, M | 1 |
| Heddle, R | 1 |
| Calvert, AF | 1 |
| Bailie, MB | 2 |
| Dahm, LJ | 1 |
| Peters-Golden, M | 1 |
| Harris, RR | 1 |
| Carter, GW | 1 |
| Roth, RA | 2 |
| Chapoutot, C | 1 |
| Perney, P | 1 |
| Le Bricquir, Y | 1 |
| Lavabre-Bertrand, T | 1 |
| Ramos, J | 1 |
| Blanc, F | 1 |
| Pearson, JM | 1 |
| Fink, GD | 1 |
| Westerman, DA | 1 |
| Schwarer, A | 1 |
| Grigg, AP | 1 |
| Weissman, SB | 1 |
| Sinclair, GI | 1 |
| Green, CL | 1 |
| Fissell, WH | 1 |
| Shuster, J | 1 |
| Freeman-Narrod, M | 1 |
| Bergstresser, PR | 1 |
| Schreiber, SH | 1 |
| Weinstein, GD | 1 |
| McDonald, CJ | 1 |
| Ottolenghi, F | 1 |
| Andreassi, L | 1 |
| Delage, C | 1 |
| Lagacé, R | 1 |
| Haghbin, M | 1 |
| Tan, CC | 1 |
| Clarkson, BD | 1 |
| Miké, V | 1 |
| Burchenal, JH | 1 |
| Murphy, ML | 1 |
| Herzberg, JJ | 1 |
| Moschella, SL | 1 |
| Greenwald, MA | 1 |
3 reviews available for hydroxyurea and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
[Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test].
Topics: Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Fatal Outcome; Humans; Hydroxyurea; I | 2014 |
Gemtuzumab ozogamicin in acute myeloid leukemia revisited.
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2014 |
3 trials available for hydroxyurea and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therap | 2013 |
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; California; Chemi | 2002 |
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Asthma; Chemical and Drug Induced Liver In | 2007 |
26 other studies available for hydroxyurea and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Chemical and Drug Induced Liver Injury; Collaborative Cross | 2020 |
Identification of key genes and pathways and therapeutic agents in cadmium-treated liver cells: A bioinformatics study.
Topics: Apoptosis Regulatory Proteins; Cadmium; Chemical and Drug Induced Liver Injury; Computational Biolog | 2017 |
Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity.
Topics: Alkylation; Anti-Asthmatic Agents; Binding, Competitive; Chemical and Drug Induced Liver Injury; Chr | 2007 |
Hydroxyurea induced acute elevations in liver function tests.
Topics: Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Hydroxyure | 2008 |
High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 1980 |
Hydroxyurea induced hepatitis.
Topics: Chemical and Drug Induced Liver Injury; Humans; Hydroxyurea; Male; Middle Aged; Psoriasis | 1980 |
Leukotrienes and alpha-naphthylisothiocyanate-induced liver injury.
Topics: 1-Naphthylisothiocyanate; Acetamides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcimycin; | 1995 |
[Acute cytolytic hepatitis caused by hydroxycarbamide].
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Hydroxyurea; Male; Nucleic Acid Synthesis Inh | 1997 |
Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration.
Topics: Administration, Oral; Alanine Transaminase; Animals; Azepines; Blood Platelets; Chemical and Drug In | 1997 |
Hydroxyurea-induced fever and hepatitis.
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fever; Humans; Hydroxyurea; Male; Middle Aged; | 1998 |
Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Seropositivity; Humans; | 1999 |
Hydroxyurea and hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Drug Monitoring; Female; HIV Infections; Humans; Hydr | 2000 |
Choline antagonism of methotrexate liver toxicity in the rat.
Topics: Animals; Chemical and Drug Induced Liver Injury; Choline; Hydroxyurea; Liver; Liver Diseases; Male; | 1977 |
Systemic chemotherapy for psoriasis: a national survey.
Topics: Adult; Azauridine; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Utiliz | 1976 |
Cutaneous uses of the antiproliferative drugs.
Topics: Administration, Topical; Antimetabolites; Azauridine; Bleomycin; Chemical and Drug Induced Liver Inj | 1974 |
[Limitations and risks of therapy of psoriasis with amethopterin and hydroxyurea].
Topics: Adult; Aged; Blood Coagulation Disorders; Chemical and Drug Induced Liver Injury; Chromosome Aberrat | 1971 |
[Hepatic peliosis: possible etiologic role of medication].
Topics: Aged; Allopurinol; Chemical and Drug Induced Liver Injury; Humans; Hydroxyurea; Iatrogenic Disease; | 1973 |
Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol).
Topics: Administration, Oral; Adolescent; Age Factors; Antineoplastic Agents; Asparaginase; Carmustine; Chem | 1974 |
[Proceedings: Immunosuppression and treatment of psoriasis using cytostatic agents].
Topics: Aged; Antineoplastic Agents; Azathioprine; Bibliographies as Topic; Chemical and Drug Induced Liver | 1973 |
Psoriasis with hydroxyurea. An 18-month study of 60 patients.
Topics: Adult; Aged; Anemia; Chemical and Drug Induced Liver Injury; Drug Resistance; Female; Humans; Hydrox | 1973 |